PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor

Liangrong Shi1,2,3, Lujun Chen1,3, Changping Wu1,2,3, Yibei Zhu4, Bin Xu1,3, Xiao Zheng1,3, Mingfen Sun1,3, Wen Wen4, Xichao Dai1,2,3, Min Yang1,2,3,4, Quansheng Lv4, Binfeng Lu5, and Jingting Jiang1,3

Abstract

Purpose: Radiofrequency ablation (RFA) has been shown to elicit tumor-specific T-cell immune responses, but is not sufficient to prevent cancer progression. Here, we investigated immune-suppressive mechanisms limiting the efficacy of RFA.

Experimental Design: We performed a retrospective case-controlled study on patients with synchronous colorectal cancer liver metastases who had received primary tumor resection with or without preoperative RFA for liver metastases. Tumor-infiltrating T cells and tumoral PD-L1 expression in human colorectal cancer tissues were analyzed by immunohistochemistry. T-cell immune responses and PD-1/PD-L1 expression were also characterized in an RFA mouse model. In addition, the combined effect of RFA and PD-1 blockade was evaluated in the mouse RFA model.

Results: We found that RFA treatment of liver metastases increased not only T-cell infiltration, but also PD-L1 expression in primary human colorectal tumors. Using mouse tumor models, we demonstrated that RFA treatment of one tumor initially enhanced a strong T-cell–mediated immune response in tumor. Nevertheless, tumor quickly overcame the immune responses by inhibiting the function of CD8+ and CD4+ T cells, driving a shift to higher regulatory T-cell to Teff ratio, and upregulating PD-L1/PD-1 expression. Furthermore, we established that the combined therapy of RFA and anti–PD-1 antibodies significantly enhanced T-cell immune responses, resulting in stronger antitumor immunity and prolonged survival.

Conclusions: The PD-L1–PD-1 axis plays a critical role in dampening RFA-induced antitumor immune responses, and this study provides a strong rationale for combining RFA and the PD-L1/PD-1 blockade in the clinical setting.

Cancer Res; 22(5); 1173–84. ©2016 AACR.

Introduction

Radiofrequency ablation (RFA) is widely used as a local treatment for tumors such as small hepatocellular carcinomas, renal cancer, and solitary colorectal cancer liver metastases (CRLM; refs. 1–3). RFA induces localized coagulation necrosis and leads to the release of large amounts of cellular debris in situ, which can serve as a source of tumor antigens to elicit host adaptive immune responses against tumors (4). Several studies on preclinical animal models have shown that localized tumor ablation by RFA can induce systemic T-cell–mediated antitumor immunity (5–7). Antigen-specific T-cell immune responses were also observed in patients with hepatic tumors after RFA therapy (8, 9). However, the RFA-induced immune responses are not sufficient to prevent tumor recurrence. The underlying mechanisms remain obscure.

Programmed death-ligand 1 (PD-L1; officially called CD274), an important immune checkpoint molecule, is often upregulated on tumor cells and tumor-associated myeloid cells. It impairs T-cell–mediated immune responses upon engagement with its cognate co-inhibitory receptor PD-1 (officially called PDCD1), which is always highly expressed on tumor-infiltrating lymphocytes (TIL; refs. 10–12). PD-L1 expression can be induced by pro-inflammatory cytokines, especially type II IFN, as an important self-limiting mechanism to prevent rampant autoimmunity (11, 13). Recent studies show that PD-L1 expression on tumor cells is associated with T-cell infiltration, suggesting that PD-L1 is actively involved in suppressing antitumor immune responses in the tumor microenvironment (TME; refs. 13–15). Whether the PD-L1–PD-1 axis is involved in modulating the antitumor T-cell immune responses induced by RFA is unclear.

The objective of this investigation was to study the RFA-induced immune responses in tumor tissues from cancer patients and tumor-bearing mice. We first examined tumor specimens from a unique cohort of colorectal cancer patients to establish whether RFA induces immune responses against tumor and potential involvement of PD-L1/PD-1 in limiting such immune responses. Mouse models were then used to characterize RFA-induced immune responses and PD-L1/PD-1–mediated immune...
Translational Relevance

Accumulating evidence suggests that efficacy of the anti-PD-1 therapy is closely associated with pre-existing antitumor immune responses. Therefore, eliciting tumor-specific T-cell immune responses should synergize with current “checkpoint” therapies. We first demonstrated that RFA increased T-cell infiltration as well as PD-L1 expression in tumor microenvironment in a unique cohort of patients with synchronous colorectal liver metastases. Using mouse tumor models, we demonstrated that the PD-L1–PD-1 axis was involved in limiting RFA-elicited T-cell immune responses. The combined therapy of RFA and PD-1 blockade synergistically enhanced T-cell–mediated immune responses and tumor rejection. Our data provide a strong rationale for combining RFA and the PD-L1/PD-1 blockade therapy in the clinical setting.

Materials and Methods

Study patients

Patient selection and study: A patient database was queried for all patients having colorectal cancer from January 2007 to December 2013 at The Third Affiliated Hospital of Soochow University. A total of 391 consecutive patients with synchronous liver metastases (LM) were initially included in this study. Among them, 38 patients who received initial hepatic RFA followed by primary tumor resection were included in the RFA group, whereas other 40 patients who received initial primary tumor resection were identified as the non-RFA group. The other 313 patients were excluded for: preoperative chemotherapy and/or radiotherapy or other types of cancer treatment (242 patients), emergency surgery for complications related to primary tumor (45 patients), and initial hepatectomy (19 patients). In addition, 7 patients who had no matched endoscopic biopsy (EB) specimen were also excluded. Paired preoperative biopsy and resected tumor (RT) specimens were matched as the non-RFA group. The other 313 patients were excluded for: preoperative chemotherapy and/or radiotherapy or other types of cancer treatment (242 patients), emergency surgery for complications related to primary tumor (45 patients), and initial hepatectomy (19 patients). In addition, 7 patients who had no matched endoscopic biopsy (EB) specimen were also excluded. Paired preoperative biopsy and resected tumor (RT) specimens of all 78 patients included were collected for immunohistochemical staining. Clinical data, including age, gender, location of primary tumor and number of LM, were obtained from the database. All RT specimens were reviewed and classified according to the 7th edition of International Union Against Cancer (UICC) TNM staging system. The study design is outlined in Supplementary Fig. S1. This study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Soochow University.

RFA treatment for colorectal cancer patients with liver metastases

RFA was performed percutaneously under compound anesthesia of vein and guided by ultrasonography (US or CT). All ablations were performed using the RITA 1500 generator (RITA Medical Systems Inc.). This system consists of a 150 Watt generator and a multitined expandable electrode (StarBurst XL, RITA). The multitined expandable electrode consists of a 15-gauge insulated cannula and nine individual electrode tines of 10 to 15 cm in length. It was deployed in situ after ultrasound or CT-guided placement of the needle electrode into the target tumor. For tumors less than 3.0 cm in diameter, the multitined expandable electrode was deployed into the center of the tumor. Each application of RFA energy lasted for 15 to 25 minutes to gain a 5.0 cm ablation zone. For tumors larger than 3.0 cm, multiple overlapping zones of ablation were needed for the destruction of the tumor and a surrounding rim of non-tumor liver. For patients with more than one lesion, the tumors were ablated separately.

Immunohistochemistry procedures and evaluation

Formalin-fixed, paraffin-embedded tissues were processed for immunohistochemical staining with antibodies for PD-L1 (1:500, clone: SP142, Spring Bioscience), which has been used in prior clinical studies (16, 17), CD4 (clone: SP35, Maixin Biotechnology Co.), and CD8 (clone: SP16, Maixin Biotechnology Co.). The quantification of PD-L1 staining for tumor cells and lymphocytes were completed in 5% to 10% increments as previously described (14). Positive PD-L1 expression was defined as ≥5% cells with membranous staining. An adjusted score representing PD-L1 expression on lymphocytes was calculated as the percentage of lymphocytes stained positive for PD-L1 multiplied by the extent of lymphocytic infiltration (0 = absent, 1 = focal, 2 = moderate, and 3 marked; ref. 18). PD-L1 staining in melanoma and human placenta specimens was used as positive control (Supplementary Fig. S2). The evaluation of the number of TIL has been described previously (19). In brief, tumor-infiltrating T cells in tumor nest were counted as follows: five areas in tumor nest with the most intense T lymphocytes infiltration were selected at low magnification (×40), and subsequently counted and recorded at high-power field (HPF, ×200 magnification). Results from the five areas were averaged and used in the statistical analysis.

Cell lines and cell culture

The mouse colon cancer cell line CT26, the mouse melanoma cancer cell line B16, and the mouse breast cancer cell line 4T1 were obtained from Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences.

Animal models and treatments

A total of 1 × 10⁶ CT26 or B16 cells were symmetrically injected i.d. into male BALB/C and C57BL/6 mice on bilateral flanks, respectively. Treatments were initiated when the tumor volume reached about 500 mm³. RFA was carried out only for the tumor on the right flank. RFA was performed using a 17-gauge single ablation electrode (RITA Medical Systems Inc.) with 1 cm active tip inserted percutaneously and orthogonal to the skin in the center of the tumor. Treatments were administered for 3.5 to 4.5 minutes at the target temperature of 70°C to ensure complete ablation of the target tumors. PD-1 blockade was accomplished by administrating 200 μg anti–PD-1 (clone: J43, BioXCell) through i.p. injection to mice every 3 days for a total of four times. To deplete CD8⁺ T-cell, 250 μg anti-CD8 (clone 2.43, Bio-XCell) was delivered per mouse four times by i.p. injection every 3 days, starting from 1 day before RFA. Perpendicular diameters of the tumor on the left flanks were measured using calipers every 3 days. Tumor size was calculated using the formula L × W, where L is the longest dimension and W is the perpendicular dimension.
Flow cytometric analysis

The tumor lymphocytes were harvested according to the method described in our previous study (20). In brief, the tumor masses were removed, minced, and digested with collagenase and hyaluronidase solution. The cell suspension was filtered through a cell mesh and resuspended in Hank’s media plus 1% FCS for further analysis. Antibodies to PD-L1 (MIH5), PD-1 (RPMI-30), CD4 (GK1.5), CD8 (53-6.7), IFN-γ (XMG1.2), TNF-α (MP6-XT22), CD3 (145-2c11), Gr1 (RB6-8C5), CD11b (M1/70), CD45 (30-F11), FOXP3 (FJK-16S), CD11c (N418), and Tim-3 (B8.2C12) antibodies were purchased from Biolegend. Flow cytometric analysis was performed using a FACS flow cytometer (Becton Dickinson). For intracellular cytokine staining, harvested cells were stimulated with PMA (10 ng/mL) and ionomycin (1 μg/mL) for 4 h and incubated for the last 1 h with brefeldin A (10 μg/mL). IFNγ and TNFα producing cells were examined with flow cytometry.

ELISPOT assay

Elispot assay was performed according to the instructions of the instrument manufacturer and as described before (21). Enzyme-linked immunosorbent spot (ELISPOT) plates (MABTECH AB, Sweden, Product code: 3321-APT-4) were washed four times with sterile PBS (200 μL/well) and incubated with medium containing 10% serum for 30 minutes at room temperature. 4T1 breast cancer cells were pulsed with 10 μg/mL of AH1 peptide (SPSYVYHQF) overnight. A total of 106 CD8+ T cells isolated from spleen or draining lymph node (DLN) were plated in quadruplicate to be cocultured with pulsed or non-pulsed 106 4T1 cells. These cells were later stimulated with 1 mmol/L of phorbol 12-myristate 13-acetate and 10 ng/mL of ionomycin as positive controls and with medium alone as negative controls. The plates were incubated in a 37°C humidified incubator with 5% CO2 for 24 hours. Rat anti-mouse IFNγ mAb (R4-6A2-biotin, 1 μg/mL) was used for detection. After 2-hour incubation with detection antibody, the plates were washed and incubated with Streptavidin-ALP for 1 hour at room temperature. Finally, substrate solution (BCIP/NBT-plus) was added to develop spots and analysis was done using an ELISPOT Plate Reader (isSPOT, German).

Quantitative real-time PCR

The mRNA levels of IFNγ, TNFα, PD-1, PD-L1, and the reference gene β-actin were measured by real-time PCR machine, ABI 7500 (Applied Biosystem). In brief, total RNA was extracted from tissues, according to the manufacturer’s instructions, using a total RNA purification kit (Shenergy Biocolor BioScience & Technology Company). The quality of the RNA was determined by measuring the absorbance at 260/280 nm. Using the First Strand cDNA Synthesis Kit (Fermentas), according to the manufacturer’s instructions, 2 μg total RNA was reverse transcribed to cDNA. The primers and TaqMan probes of IFNγ, TNFα, PD-1, PD-L1, and the reference gene β-actin were designed according to the National Center for Biotechnology Information (NCBI) database by using Primer Premier 5.0 software (Palo Alto). The sequences of all primers used in this study are listed in Supplementary Table S1.

Statistical analysis

Differences in distribution of selected demographic and clinical characteristics between RFA and non-RFA groups were performed using the Student t test and Fisher χ2 test. We examined correlation between PD-L1 expression on tumor cells and intensity of T-cell infiltration, using the pearman test. The Wilcoxon signed rank test was used to test differences in intensity of T-cell infiltration and PD-L1 expression between matched specimens (EB vs resected primary tumor) within RFA and non-RFA groups, respectively. The Mann–Whitney U test was used to examine differences between two groups. Logistical regression analysis was used to identify potential associated with increase of PD-L1 expression in RT specimens compared with EB specimens.

Results

Both the number of TILs and expression of PD-L1 were increased in the primary tumor upon RFA treatment of colorectal hepatic metastases

It has been shown that RFA induced systemic tumor antigen-specific T-cell responses in human carcinoma. However, there are insufficient studies on the immune modulation of TME outside of the ablation zone. To study how RFA modifies TME in human cancer patients, we performed a retrospective study of a unique cohort of patients who suffered from synchronous CRCLM. Thirty-eight patients who received preoperative RFA for LM followed by primary tumor resection were assigned to the RFA group, whereas 40 patients who received primary tumor resection without RFA were included in the non-RFA group. There was no significant difference in demographic, clinical characteristics, and staging between the RFA and non-RFA groups (Supplementary Table S2). The median time interval from RFA to primary tumor resection was 6 days (range, 4–10 days).

We first sought to determine whether RFA induces T-cell immune responses in TME using the frequency of CD4+ and CD8+ TIL as an indicator. There was no difference in the number of infiltrating T cells between RFA and non-RFA groups before treatment, as shown in results obtained using the EB specimens (Mann–Whitney test, P = 0.268 for CD8+ T-cell, P = 0.812 for CD4+ T cell, Table 1). Interestingly, however, a higher number of tumor-infiltrating T cells were observed in the RFA group compared with that of the non-RFA group in RT specimens (Mann–Whitney test, P < 0.001 for CD8+ T cell, P = 0.001 for CD4+ T cell, Table 1). In addition, the CD8 to CD4 ratio was higher in the RFA group compared with the non-RFA group in the RT specimens (Fisher χ2 test, P = 0.002, Table 1, Fig. 1A, Supplementary Fig. S3). These data indicated that RFA elevated T-cell immune responses in TME.

We also compared the intensity of T-cell infiltration between matched EB and RT specimens on case by case basis. As shown in a previous study (22), for the non-RFA group, the number of infiltrating T cell in RT specimen was similar to that in EB specimen (Wilcoxon Signed Ranks test, P = 0.117 for CD8+ and P = 0.754 for CD4+, respectively). In contrast, in the RFA group, the frequency of infiltrating CD8+ and CD4+ T cell was significantly increased in the RT specimens when compared with the EB
To more accurately demonstrate the impact of hepatic RFA on the PD-L1 expression in primary tumors, we introduced a new variable "ΔPD-L1" (ΔPD-L1 on tumor cell = percentage of positive cells in the RT specimen—percentage of positive cells in the EB specimen; ΔPD-L1 on immune cell = adjusted IHC score in the RT specimen—IHC score in the EB specimen). This variable also helps control for variations in the baselines that may affect the quantification of PD-L1 expression. ΔPD-L1 on both tumor cells and immune cells were higher in the RFA group than in the non-RFA group (Mann–Whitney U test, P = 0.0004 and P < 0.001, respectively, Fig. 1D and G). In addition, after adjustment for other variables, including sex, year, tumor grade, histologic type, numbers of LM, the site of primary tumor, regional lymph node status, we revealed a significant association between hepatic RFA and increased PD-L1 expression in primary tumor (OR, 25.71; 95% confidence interval (CI), 4.52–146.16; P < 0.001; Supplementary Table S3). Collectively, this suggests that RFA of metastatic tumors induced T-cell–mediated immune responses against primary tumor as well as PD-L1 expression as a self-limiting mechanism.

RFA induces modest and short-lived growth inhibition of distant tumors

To further study RFA-induced immune responses, mice were inoculated with CT26, a murine colon cancer cell line that has shown sensitivity to checkpoint blockade (23), on bilateral flanks. RFA was then performed on the tumor at the right flank once the tumor volume reached about 500 mm³. The growth of the tumor on the left flank was monitored. A slight halt of growth of the contralateral tumor was observed after the RFA. However, on around days 6 to 9, the contralateral tumor restored its progressive growth (Fig. 2A). We also confirmed this finding with the B16 melanoma model (Fig. 2B).

Infiltrating T cells in the distant tumor displayed a potent but transient antitumor effector function, which waned as the tumor regained its growth

To better understand the magnitude and duration of antitumor immune responses induced by RFA, we performed immune analysis at an earlier and later time points in the distant CT26 tumor after RFA treatment. On day 3, about 2-fold increase of the percentage of the CD45+ T-cell infiltration was observed in the distant tumor of the RFA-treated mice. Interestingly, the frequency of CD45+ infiltrating cells increased further on day 8 (Supplementary Fig. S5A–S5C). This indicated that localized tumor specimens (Wilcoxon Signed Ranks test, P = 0.003 and P = 0.002, respectively). In addition, in the RFA group, a higher CD8 to CD4 ratio was found in the RT specimens when compared with the EB specimens (Fisher χ² test, P = 0.002, Fig. 1A, Supplementary Fig. S3), consistent with the idea that a strong CD8+ T-cell–mediated immune response is promoted by RFA.

We also characterized the PD-L1 expression in tumor tissues because it is an important checkpoint molecule limiting T-cell responses. PD-L1 expression was found on both tumor cells and tumor-associated immune cells. Among 78 EB specimens, 18 (23.1%; 9 each for the RFA and non-RFA groups) showed positive PD-L1 expression on tumor cells. 31 (39.7%; 14 of the RFA group and 17 of the non-RFA group) showed positive PD-L1 expression on infiltrating immune cells. Among the RT specimens, 25 (32.1%; 15 of RFA group and 10 of the non-RFA group) had PD-L1 expression on tumor cells, whereas 40 (51.3%; 22 of the RFA group and 18 of the non-RFA group) had PD-L1 expression on immune cells. In all groups, levels of PD-L1 expression on tumor cells were significantly associated with PD-L1 expression on immune cells. Both EB and RT specimens showed a significant association between PD-L1 expression on tumor cells and the intensity of CD8+ T-cell infiltration (Spearman correlation, P = 0.001 for EB and P < 0.001 for RT specimens; Supplementary Fig. S5A and S5C). In contrast, there is no significant association between tumor PD-L1 expression and intensity of CD4+ T-cell infiltration (Spearman correlation, P = 0.159, for EB and P = 0.065 for RT specimens; Supplementary Fig. S4B and S4D).

We sought to determine whether RFA treatment resulted in changes of PD-L1 expression. In the non-RFA group, PD-L1 expression in the RT specimens was similar to that in the matched EB specimen (Wilcoxon signed rank test, P = 0.234 for PD-L1 expression on tumor cells and P = 0.194 for that on immune cells, Fig. 1B and E). In contrast, within the RFA group, an increase of PD-L1 expression was observed not only on tumor cells but also on immune cells in the RT specimens when compared with matched EB specimens (Wilcoxon signed ranks test, P = 0.0001 and P = 0.0003, respectively; Fig. 1A, C, and F; Supplementary Fig. S3). Interestingly, 78.6% of the cases that were PD-L1 positive at the initial biopsy had increases in PD-L1 expression after RFA. Moreover, 33.3% of the cases that were PD-L1 negative at the initial biopsy became PD-L1 positive for the matched RT specimens after RFA.

To more accurately demonstrate the impact of hepatic RFA on the PD-L1 expression in primary tumors, we introduced a new variable "ΔPD-L1" (ΔPD-L1 on tumor cell = percentage of positive cells in the RT specimen—percentage of positive cells in the EB specimen; ΔPD-L1 on immune cell = adjusted IHC score in the RT specimen—IHC score in the EB specimen). This variable also helps control for variations in the baselines that may affect the quantification of PD-L1 expression. ΔPD-L1 on both tumor cells and immune cells were higher in the RFA group than in the non-RFA group (Mann–Whitney U test, P = 0.0004 and P < 0.001, respectively, Fig. 1D and G). In addition, after adjustment for other variables, including sex, year, tumor grade, histologic type, numbers of LM, the site of primary tumor, regional lymph node status, we revealed a significant association between hepatic RFA and increased PD-L1 expression in primary tumor (OR, 25.71; 95% confidence interval (CI), 4.52–146.16; P < 0.001; Supplementary Table S3). Collectively, this suggests that RFA of metastatic tumors induced T-cell–mediated immune responses against primary tumor as well as PD-L1 expression as a self-limiting mechanism.

### Table 1. Analysis of the IHC staining of CD8 and CD4 in matched EB and RT specimens

<table>
<thead>
<tr>
<th></th>
<th>EB</th>
<th></th>
<th></th>
<th></th>
<th>RT</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-RFA</td>
<td></td>
<td></td>
<td></td>
<td>Non-RFA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td></td>
<td></td>
<td></td>
<td>n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>12 (30.0)</td>
<td></td>
<td></td>
<td></td>
<td>14 (35.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>9 (22.5)</td>
<td></td>
<td></td>
<td></td>
<td>9 (22.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21–40</td>
<td>12 (30.0)</td>
<td></td>
<td></td>
<td></td>
<td>11 (27.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;40</td>
<td>7 (17.5)</td>
<td></td>
<td></td>
<td></td>
<td>6 (15.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>8 (20.0)</td>
<td></td>
<td></td>
<td></td>
<td>9 (22.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>10 (25.0)</td>
<td></td>
<td></td>
<td></td>
<td>11 (27.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21–40</td>
<td>13 (32.5)</td>
<td></td>
<td></td>
<td></td>
<td>12 (30.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;40</td>
<td>9 (22.5)</td>
<td></td>
<td></td>
<td></td>
<td>8 (20.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD8:CD4 ratio</td>
<td>1.000</td>
<td></td>
<td></td>
<td></td>
<td>0.007</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>EB</th>
<th></th>
<th></th>
<th></th>
<th>RT</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-RFA</td>
<td></td>
<td></td>
<td></td>
<td>Non-RFA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td></td>
<td></td>
<td></td>
<td>n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: EB = EB specimen; RT = RT specimen; P values were calculated using Wilcoxon signed ranks test or Fisher χ² test.*
Ablation induced a sustained inflammatory response in the distant tumor even at a later stage when tumor had restored rapid growth. The T-cell infiltration was characterized by increased frequencies of CD4+ and CD8+ T cells on days 3 and 8 (Fig. 3A–C; Supplementary Fig. S5D and S5E). The percentage of regulatory T cell (Treg) was reduced in RFA-treated mice on day 3 (Fig. 3D and E). This resulted in an increase in the ratio of CD8+ versus Treg (Fig. 3F), indicating a shift of immune balance toward antitumor immunity on day 3 upon RFA. However, the shift was temporary. On day 8, the percentage of Treg was at a similar level to that in the untreated mice (Fig. 3D and E). On day 8 after RFA, the CD8+ T cell to Treg ratio was significantly decreased as comparing with that on day 3 (P < 0.001), whereas it was still modestly higher due to an increase in CD8+ T-cell infiltration (Fig. 3F). Similar results were obtained using the B16 melanoma tumor model (Supplementary Fig. S6A–S6G). These results suggest that...
an antitumor immune response is induced by RFA, but is tamed by the active immune suppression in TME.

To determine the function of TIL, we analyzed the ability of T cells to produce IFNγ and TNFα by flow cytometry. On day 3, the percentage of IFNγ+ and TNFα+ CD8+ TIL was significantly increased in RFA-treated mice when compared with untreated mice. However, the percentage of IFNγ+ and TNFα+ CD8+ TIL was markedly decreased on day 8 and was similar to that in the untreated mice (Fig. 3G and H). Similar results were observed on CD4+ TIL (Fig. 3I and J). In contrast, IFNγ and TNFα mRNA expression in tumors were 4- to 5-fold higher in RFA-treated mice compared with untreated mice on day 3 (Fig. 3I and K). In contrast, IFNγ and TNFα mRNA levels were sharply decreased on day 8 (Fig. 3J and K). These data indicate that TIL underwent functional exhaustion at the later stage after RFA when tumor regression was reversed.

Expression of PD-L1 and PD-1 in the distant tumor upon RFA treatment

Our data showed that both the number of TIL and expression of PD-L1 were increased in the human primary tumor upon RFA of colorectal hepatic metastases. Here, we sought to examine PD-L1 expression in the TME in CT26 mouse colon cancer model. On day 3, a rapid upregulation of PD-L1 expression was observed on CD45+ cells isolated from tumor tissues. The proportion of PD-L1+CD45+ cells increased from about 10% to 23% (Fig. 4A and B). Similarly, PD-L1+ expression increased in tumor associated DCs, MDCs, and macrophages upon RFA (Fig. 4A and B). On day 8, we observed a further increase of PD-L1 expression on all cell populations in the RFA group (Fig. 4A and C). In contrast, we did not detect PD-L1 expression on splenic CD11c+ cells, F4/80+ cells, and CD11b+Gr1+ cells (Supplementary Fig. S7A). In addition, we showed that RFA treatment also led to an increase in PD-L1 expression in B16 tumor tissues (Supplementary Fig. S6H–S6I). These data indicate that the tumor inflammatory mienvironment induced by RFA plays a direct role in the upregulation of PD-L1 expression.

Further analysis showed that approximately 70% of CD8+ and 40% of CD4+ TIL expressed PD-1 in untreated CT26 tumor-bearing mice. On day 3 after RFA, we observed about a 20% decrease in PD-1+CD8+ TIL cells compared with those in the untreated mice. However, the frequency of PD-1+CD8+ TIL increased to more than 80% on day 8 in RFA-treated mice and was slightly higher than those in the untreated mice (Fig. 4D and E). The PD-1+ expression on CD4+ T cells, however, showed no difference between two groups on both days 3 and 8 (Fig. 4F).

We did not detect large numbers of PD-1+ splenic CD4+ and CD8+ T cells on both days 3 and 8 (Supplementary Fig. S7B and S7C). In B16 tumor, we detected a slight but statistically significant increase of PD-1+ expression on both CD4+ and CD8+ TIL on day 8 after RFA (Supplementary Fig. S6K–S6N).

Our data also showed a significant increase in PD-L1 mRNA in CD45+ cells and total tumors on both days 3 and 8 in CT26 tumor (Fig. 4G). The mRNA level of PD-1 in total tumor had no significant change on day 3 after RFA, but increased 3-fold on day 8 (Fig. 4H). In accordance with PD-1 protein expression on CD8+ TIL, PD-1 mRNA also decreased significantly on day 3, and then increased on day 8 in the CD8+ TIL population in the RFA group compared with the non-RFA group (Fig. 4H). Collectively, these data suggest that the PD-L1/PD-1 axis is involved in limiting the efficacy of RFA treatment through immune suppression.

In addition, we found that Tim-3, CD160, CD244, and eomes, which are typical exhaustion markers (24), were expressed at higher levels on both CD8+ and CD4+ TIL 8 days after RFA treatment (Supplementary Fig. S8A–S8F). In contrast, only CD160 and CD244 were expressed at higher levels on day 3 in the RFA group compared with the control. Therefore, in addition to the PD-L1/PD-1 axis, other markers of T-cell exhaustion were also induced to higher levels upon RFA treatment.

The combination of RFA and anti–PD-1 treatment synergistically inhibited the growth of the distant tumor through CD8+ T cells

It has been demonstrated that the efficacy of the PD-1 blockade therapy is closely associated with pre-existing tumor antigen-specific T-cell immune responses (16, 25). Because RFA induced T-cell accumulation and upregulated PD-L1 expression in distant tumor tissues, we postulated that subsequent anti–PD-1 therapy would enhance the antitumor immunity and improve the treatment efficacy of RFA. To test the hypothesis, CT26-bearing mice were treated with RFA plus an isotype control antibody, RFA plus anti–PD-1 monoclonal antibodies (mAbs; RFA+α–PD-1), anti–PD-1 mAbs alone (α–PD-1), or left without treatment (Fig. 5A). Because CD8+ TIL were significantly increased in tumors after RFA treatment, we also sought to determine whether CD8+ T cells...
mediate the effect of RFA and PD-1 blockade using CD8-depleting mAbs. No recurrence occurred in the ablation zone. RFA had a modest inhibitory effect on contralateral tumor progression. Anti–PD-1 itself also led to a modest inhibition of tumor growth, consistent with a previous observation (23). In contrast, we observed significant tumor regression, much longer duration of inhibition of tumor growth and prolonged survival in the RFA/anti–PD-1–treated mice, as compared with mice in the no-treatment or single treatment groups (Fig. 5B and C). Depletion of CD8+ T cells completely eliminated the inhibition of tumor growth.
growth of mice with the combined treatment (Fig. 5B and C). These data indicate that RFA and PD-1 blockade further enhance CD8+ T-cell–mediated antitumor immunity.

Combination of RFA and anti–PD-1 mAbs administration further enhanced tumor antigen-specific T-cell responses and increased Teff to Treg ratio in the distant tumor

To better determine synergistic antitumor immune responses of the combination of RFA and anti–PD-1, we examined the T-cell response in mice treated with RFA, α-PD-1, RFA + α-PD-1, and no treatment. On day 12, the frequency of both CD34+ and CD8+ cells was higher in RFA-treated and α-PD-1 mAbs-treated mice than in untreated mice (Fig. 5D–F, Supplementary Fig. S9A and S9B). In the RFA plus α-PD-1 mAbs group, the infiltrating CD45+ and CD8+ cells were increased as compared with the RFA or α-PD-1 alone (Fig. 5D–F, Supplementary Fig. S9A and S9B). Importantly, the percentage of IFNγ+ and TNFα+ CD8+ TIL in the RFA plus α-PD-1 mAbs-treated mice increased 3-fold more than the RFA-treated mice and 2-fold more than α-PD-1 mAbs-treated mice (Fig. 5G and H). Meanwhile, the number of CD4+ TIL and the percentage of IFNγ+ and TNFα+ CD4+ TIL were increased in mice receiving combined therapy (Fig. 5G, I, and Supplementary Fig. S9C). Quantitative real-time PCR analysis showed that mRNA levels of IFNγ and TNFα in contralateral tumor were significantly elevated in the RFA plus α-PD-1–treated mice when compared with the RFA or the α-PD-1 treatment alone groups (Fig. 5J). These data suggest that blockade of the PD-L1–PD-1 pathway boosted RFA-induced antitumor immune responses and reversed immune suppression at the distant tumor site.

To explore whether systemic tumor antigen-specific T cells can be induced to a higher level after the combined treatment, we carried out ELISPOT assays for IFNγ secretion upon ex vivo re-stimulation of T cells with tumor antigens. CD8+ T cells isolated from spleens and DLNs were co-cultured with AH1 peptide pulsed with antigen-presenting cells (APC). Consistent with the increased number of CD8+ T cells producing IFNγ in tumor, we detected a significant increase in the number of tumor antigen-specific IFNγ-secreting cells in both spleens and DLNs from the RFA/α-PD-1–treated mice compared with the RFA or the α-PD-1 treatment alone groups (Fig. 5K). Thus, these data indicated that RFA and anti–PD-1 therapy synergistically induced adaptive tumor antigen–specific CD8+ T-cell immune responses.

The PD-L1–PD-1 pathway has been shown to be required for the abundance of Treg in the tumor sites. To assess the impact of PD-1 blockade on the balance between intratumoral Teff and Treg, we examined CD4+Foxp3+ Treg in contralateral tumor on day 12 after RFA. Our data showed that the proportion of intratumoral Treg was significantly decreased both in mice treated with RFA/anti–PD-1 and anti–PD-1 alone, leading to dramatically elevated CD8+ T-cell to Treg ratio as compared with the RFA-treated mice or anti–PD-1–treated mice (Fig. 5L–N). Collectively, these data suggest anti–PD-1 therapy reverses adaptive immunosuppression in the distant tumor through reducing Treg and increasing functional effector T cells.

**Figure 4.** PD-L1/PD-1 expression in the distant tumor after RFA treatment in the CT26 tumor-bearing mice. The CT26 tumor-bearing mice models were established and treated as described in Fig. 3. A, representative flow cytometric histograms showing PD-L1 expression on tumor and stromal cells (CD45+), total infiltrating immune cells (CD45+), dendritic cells (CD11c+), macrophages (F4/80+), and MDCs (Gr1+CD11b+) in contralateral tumor on days 3 and 8 after RFA. B, percentages of PD-L1+ cells on day 3 upon RFA. C, percentages of PD-L1+ cells on day 8. D, representative flow cytometric plots showing PD-L1 expression on CD8+ cells in CD45+ population on days 3 and 8. E, percentages of PD-L1+ cells within CD8+ cells within CD45+ cells. F, percentage of PD-L1+ cells within CD45+ cells. G, the PD-L1 mRNA level in total tumor (left) and isolated CD45+ cells (right). H, the PD-L1 mRNA level in total tumor (left) and isolated CD8+ TIL (right). Data represent cumulative results from two independent experiments with 5 mice per group (values represent means ± SEM; *, P < 0.05; ***, P < 0.001).
Besides PD-1, multiple pathways have been found to be involved in TIL exhaustion (24). In particular, we and others have found that Tim-3 was highly induced in CD4\(^+\) and CD8\(^+\) TIL in both mouse and human tumors (26–28). Interestingly, we observed a significant increase of Tim-3 on both CD8\(^+\) and CD4\(^+\) TIL upon PD-1 blockade, RFA treatment, or combination treatment (Supplementary Fig. S10A–S10D). These data suggest that additional regulatory pathways such as Tim-3 might compensate for the lack of PD-1 to induce TIL exhaustion.

**Discussion**

In this study, we have shown that localized RFA increases T-cell infiltration as well as PD-L1 expression in a distant tumor in both human patients with synchronous colorectal cancer liver metastases and tumor-bearing mice. Furthermore, using a mouse model, we demonstrated that combination of localized RFA and anti-PD-1 antibodies significantly enhanced tumor antigen-specific T-cell responses, increased intratumoral Teff to Treg ratio, and synergistically inhibited growth of the distant tumor.

It has been shown that RFA induced systemic tumor antigen-specific T-cell immune responses in human hepatocellular carcinoma (8, 9). However, these studies are limited to the analysis of peripheral immune cells but not in TME. Because of extensive application of RFA in CRCLM (2) and promotion of “liver first” treatment modality (initial liver resection/ablation followed by primary tumor resection) in resectable synchronous CRCLM (29), we could obtain matched tumor specimens outside of the ablation zone (primary colorectal tumors) prior-RFA (EB) and post-RFA (RT). Using this novel clinical study design, we revealed a significant increase in T-cell infiltration and a higher CD8 to CD4 ratio in the primary colorectal tumor tissues after RFA for liver
metastases. These data clearly demonstrated that the localized RFA induced T-cell–mediated immune responses in a distant tumor site in human carcinoma. However, RFA is not sufficient to prevent tumor recurrence in clinic, suggesting that duration and function of RFA-induced tumor-specific T cells are inadequate. In this study, we showed that local RFA led to a small and short-lived inhibition of distant tumors in mouse models. We further showed that frequency of IFNγ and TNFα-producing CD8⁺ TIL increased at the early stage after RFA but diminished overtime. In addition, we found that the PD-L1 expression – mediated suppression of RFA-induced antitumor immunity. Besides PD-L1 and PD-1, CTLA-4 has been shown to inhibit thermal ablation–induced antitumor activities (4, 30, 31). Aside from immune inhibitory pathways, it has been shown that various cytokines that are used to enhance T-cell homeostasis and T-cell immune responses also increase the antitumor efficacy of RFA (32, 33). Thus, future combination therapy with RFA and various immune modulators can be explored in the clinical setting.

The abscopal effect we observed with RFA has been described in other tumor therapies. Notably, radiotherapy has been recently shown to induce similar antitumor effect through induction of tumor antigen–specific adaptive immune responses (34, 35). Blockade of immune checkpoints has been shown to improve the efficacy of radiotherapy on local and distant tumors in experimental systems and as well as in clinical settings (36–38). In a recent report, Victor and colleagues (39) showed a phase I clinical trial of 22 patients with advanced melanoma treated with radiotherapy and anti–CTLA-4. They also found radiotherapy combined with anti–CTLA-4 enhanced antitumor immunity, but did not prevent T-cell exhaustion in the melanoma tumor mouse model. Similar to our study, PD-L1 blockade reversed T-cell exhaustion, promoted T-cell expansion, migrate depression in the CD8/Treg ratio, and led to an optimal response in their preclinical model. Despite similarity between RFA and radiotherapy in the final outcome of induction of adaptive immunity against tumor antigens, the underlying mechanisms could differ. A recent study showed that STING but not MyD88 or TRIF is essential for radiotherapy and the cGAS–STING axis mediates innate sensing of irradiated-tumor cells (40). It remains elusive what triggers innate immunity and set off adaptive immunity in the setting of RFA and the underlying mechanism warrants further studies.

Blockade of the PD-L1–PD-1 axis has achieved remarkable efficacy in clinical trials (17, 41–45). Nevertheless, most patients who lack PD-L1 expression do not benefit from the anti–PD-1 therapy (42), suggesting that efficacy of the anti–PD-1 therapy is closely associated with pre-existing antitumor immune responses (16, 25, 46). Thus, rational combination of treatments that can induce antitumor immune responses and the anti–PD-L1/PD-1 therapy should greatly increase the number of suitable cancer patients. Recently, combining of radiotherapy and PD-L1/PD-1 blockade have been shown to synergistically enhance antitumor immunity in preclinical studies (36, 47, 48), suggesting local antitumor treatments, which can elicit immune response hold promise in providing opportunity for PD-1/PD-L1 blockade therapy.

Taube and colleagues (46) have shown that the PD-L1 expression in colorectal cancer was relatively lower in contrast with other cancer types such as melanoma, kidney cancer, and lung cancer etc. In this study, we also revealed a low frequency of PD-L1 expression. Interestingly, we demonstrated that RFA for liver metastases upregulated PD-L1 expression, which is associated with an increase in T-cell infiltration in primary colorectal cancer. On one hand, these findings indicate that RFA-stimulated antitumor immune responses are dampened by PD-L1. On the other hand, our studies strongly suggest that RFA increases the number of patients that can potentially benefit from the powerful anti–PD-L1–PD-1 therapy.

There are several potential advantages of combining RFA and the PD-L1/PD-1 blockade. First, RFA is widely used in CRCLM (49), making it feasible to explore its role in a novel combined modality. Second, RFA results in the instant release of large amounts of tumor antigens in the milieu of "danger" signals, which can potentially stimulate transient immune responses to a wide of variety of tumor antigens. Third, the PD-1 mAbs treatment has shown promising results in colorectal cancer in a phase I clinical trial (45), and a study showed that the microsatellite instable subset of colorectal cancer can be a good candidate for checkpoint blockade immunotherapy (50). Thus, these results and our study strongly support combining RFA and blockade of the PD-L1/PD-1 for the treatment of metastatic colorectal cancer patients.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: L. Shi, C. Wu, Y. Zhu, B. Lu, J. Jiang
Development of methodology: L. Chen, C. Wu, Y. Zhu, B. Lu
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Shi, L. Chen, C. Wu, M. Sun, W. Wen, X. Dai, M. Yang, Q. Lv, B. Lu
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C. Wu, B. Xu, B. Lu
Writing, review, and/or revision of the manuscript: L. Shi, L. Chen, C. Wu, X. Zheng, X. Dai, B. Lu, J. Jiang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Shi, C. Wu, Y. Zhu, B. Lu
Study supervision: C. Wu, B. Lu

Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (nos. 30972703, 81171658, 81201741, 31428005, 31570877, 31570908, and 81301960). The project was also supported by the NIH through grants (no. R21CA167229, U11 RR024153, U11TR000005, and IP50 CA097190), Roswell Park Cancer Institute/University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Programs of Research Excellence Grants (P50CA159581), and the Key R&D Projects of Science and Technology Department of Jiangsu Province (BE201333 and BE2016343).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 9, 2015; revised September 4, 2015; accepted September 25, 2015; published online March 1, 2016.

References


PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor
Liangrong Shi, Lujun Chen, Changping Wu, et al.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/22/5/1173

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2016/03/02/22.5.1173.DC1

Cited articles
This article cites 50 articles, 21 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/22/5/1173.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/22/5/1173.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.